{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:06:25Z","timestamp":1792101985843,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["573747\/2008-3"],"award-info":[{"award-number":["573747\/2008-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40618-017-0708-9","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T01:29:09Z","timestamp":1497317349000},"page":"1279-1288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":169,"title":["Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"A. L. L.","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. C.","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. C. M.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"C\u00e2ndido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-7472","authenticated-orcid":false,"given":"F. M.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"key":"708_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.mcna.2013.09.001","volume":"98","author":"RL Corrado","year":"2014","unstructured":"Corrado RL, Torres DM, Harrison SA (2014) Review of treatment options for nonalcoholic fatty liver disease. Med Clin N Am 98:55\u201372. doi: 10.1016\/j.mcna.2013.09.001","journal-title":"Med Clin N Am"},{"key":"708_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274\u2013285. doi: 10.1111\/j.1365-2036.2011.04724.x","journal-title":"Aliment Pharmacol Ther"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0973-6883(12)60102-9","volume":"2","author":"A Mishra","year":"2012","unstructured":"Mishra A, Younossi ZM (2012) Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol 2:135\u2013144. doi: 10.1016\/s0973-6883(12)60102-9","journal-title":"J Clin Exp Hepatol"},{"key":"708_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1055\/s-0028-1091978","volume":"28","author":"M Lazo","year":"2008","unstructured":"Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28:339\u2013350. doi: 10.1055\/s-0028-1091978","journal-title":"Semin Liver Dis"},{"key":"708_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2016.03.003","author":"MJ Chen","year":"2016","unstructured":"Chen MJ, Ho HN (2016) Hepatic manifestations of women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. doi: 10.1016\/j.bpobgyn.2016.03.003","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"708_CR6","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1210\/jc.2004-1024","volume":"90","author":"F Angelico","year":"2005","unstructured":"Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C, Violi F (2005) Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90:1578\u20131582. doi: 10.1210\/jc.2004-1024","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.4254\/wjh.v7.i15.1905","volume":"7","author":"L Vonghia","year":"2015","unstructured":"Vonghia L, Francque S (2015) Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: pathology and beyond. World J Hepatol 7:1905\u20131912. doi: 10.4254\/wjh.v7.i15.1905","journal-title":"World J Hepatol"},{"key":"708_CR8","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3390\/biom5031563","volume":"5","author":"L Xu","year":"2015","unstructured":"Xu L, Kitade H, Ni Y, Ota T (2015) Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules 5:1563\u20131579. doi: 10.3390\/biom5031563","journal-title":"Biomolecules"},{"key":"708_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3978\/j.issn.2304-3881.2014.12.04","volume":"3","author":"V Bieghs","year":"2014","unstructured":"Bieghs V, Trautwein C (2014) Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr 3:377\u2013385. doi: 10.3978\/j.issn.2304-3881.2014.12.04","journal-title":"Hepatobiliary Surg Nutr"},{"key":"708_CR10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1172\/jci57132","volume":"121","author":"CN Lumeng","year":"2011","unstructured":"Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121:2111\u20132117. doi: 10.1172\/jci57132","journal-title":"J Clin Invest"},{"key":"708_CR11","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.3748\/wjg.v16.i38.4762","volume":"16","author":"A Federico","year":"2010","unstructured":"Federico A, D\u2019Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, De Palma R (2010) Fat: a matter of disturbance for the immune system. World J Gastroenterol 16:4762\u20134772","journal-title":"World J Gastroenterol"},{"key":"708_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s40618-015-0315-6","volume":"38","author":"G Targher","year":"2015","unstructured":"Targher G, Lonardo A, Rossini M (2015) Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest 38:817\u2013825. doi: 10.1007\/s40618-015-0315-6","journal-title":"J Endocrinol Invest"},{"key":"708_CR13","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","volume":"142","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592\u20131609. doi: 10.1053\/j.gastro.2012.04.001","journal-title":"Gastroenterology"},{"key":"708_CR14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/j.1478-3231.2012.02804.x","volume":"32","author":"S Ballestri","year":"2012","unstructured":"Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day CP, Loria P (2012) Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 32:1242\u20131252. doi: 10.1111\/j.1478-3231.2012.02804.x","journal-title":"Liver Int"},{"key":"708_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54:1082\u20131090. doi: 10.1002\/hep.24452","journal-title":"Hepatology"},{"key":"708_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-2001-12930","volume":"21","author":"ES Siegelman","year":"2001","unstructured":"Siegelman ES, Rosen MA (2001) Imaging of hepatic steatosis. Semin Liver Dis 21:71\u201380","journal-title":"Semin Liver Dis"},{"key":"708_CR17","first-page":"966","volume":"87","author":"PM Yang","year":"1988","unstructured":"Yang PM, Huang GT, Lin JT, Sheu JC, Lai MY, Su IJ, Hsu HC, Chen DS, Wang TH, Sung JL (1988) Ultrasonography in the diagnosis of benign diffuse parenchymal liver diseases: a prospective study. Taiwan Yi Xue Hui Za Zhi 87:966\u2013977","journal-title":"Taiwan Yi Xue Hui Za Zhi"},{"key":"708_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMcp1514916","volume":"375","author":"CR McCartney","year":"2016","unstructured":"McCartney CR, Marshall JC (2016) CLINICAL PRACTICE. Polycystic ovary syndrome. N Engl J Med 375:54\u201364. doi: 10.1056\/NEJMcp1514916","journal-title":"N Engl J Med"},{"key":"708_CR19","doi-asserted-by":"publisher","first-page":"R219","DOI":"10.1530\/rep-14-0435","volume":"149","author":"PM Spritzer","year":"2015","unstructured":"Spritzer PM, Lecke SB, Satler F, Morsch DM (2015) Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 149:R219\u2013227. doi: 10.1530\/rep-14-0435","journal-title":"Reproduction"},{"key":"708_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40618-016-0446-4","volume":"39","author":"Y Cakiroglu","year":"2016","unstructured":"Cakiroglu Y, Vural F, Vural B (2016) The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J Endocrinol Invest 39:899\u2013907. doi: 10.1007\/s40618-016-0446-4","journal-title":"J Endocrinol Invest"},{"key":"708_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12958-016-0173-x","volume":"14","author":"V Leo De","year":"2016","unstructured":"De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F (2016) Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 14:38. doi: 10.1186\/s12958-016-0173-x","journal-title":"Reprod Biol Endocrinol"},{"key":"708_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40618-016-0582-x","volume":"40","author":"U Durmus","year":"2017","unstructured":"Durmus U, Duran C, Ecirli S (2017) Visceral adiposity index levels in overweight and\/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest 40:487\u2013497. doi: 10.1007\/s40618-016-0582-x","journal-title":"J Endocrinol Invest"},{"key":"708_CR23","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of intervention. Version 5.1.0. The Cochrane Collaboration (updated March 2011)"},{"key":"708_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135. doi: 10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"708_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1590\/S0004-28032015000200008","volume":"52","author":"MD Romanowski","year":"2015","unstructured":"Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA (2015) Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol 52:117\u2013123. doi: 10.1590\/S0004-28032015000200008","journal-title":"Arq Gastroenterol"},{"key":"708_CR26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1665-2681(19)31616-3","volume":"9","author":"Y Gutierrez-Grobe","year":"2010","unstructured":"Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N (2010) Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9:402\u2013409","journal-title":"Ann Hepatol"},{"key":"708_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/00365521.2010.539251","volume":"46","author":"N Hossain","year":"2011","unstructured":"Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM (2011) Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 46:479\u2013484. doi: 10.3109\/00365521.2010.539251","journal-title":"Scand J Gastroenterol"},{"key":"708_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jhep.2007.04.012","volume":"47","author":"C Cerda","year":"2007","unstructured":"Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M (2007) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47:412\u2013417. doi: 10.1016\/j.jhep.2007.04.012","journal-title":"J Hepatol"},{"key":"708_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.cgh.2006.10.010","volume":"5","author":"M Gambarin-Gelwan","year":"2007","unstructured":"Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W (2007) Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5:496\u2013501. doi: 10.1016\/j.cgh.2006.10.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"708_CR30","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1210\/jc.2009-2698","volume":"95","author":"MJ Chen","year":"2010","unstructured":"Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN (2010) Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 95:3332\u20133341. doi: 10.1210\/jc.2009-2698","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/humrep\/dep380","volume":"25","author":"E Vassilatou","year":"2010","unstructured":"Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I (2010) Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25:212\u2013220. doi: 10.1093\/humrep\/dep380","journal-title":"Hum Reprod"},{"key":"708_CR32","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.fertnstert.2008.12.008","volume":"93","author":"A Markou","year":"2010","unstructured":"Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G (2010) Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 93:1220\u20131226. doi: 10.1016\/j.fertnstert.2008.12.008","journal-title":"Fertil Steril"},{"key":"708_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/uog.10084","volume":"39","author":"LF Zueff","year":"2012","unstructured":"Zueff LF, Martins WP, Vieira CS, Ferriani RA (2012) Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 39:341\u2013347. doi: 10.1002\/uog.10084","journal-title":"Ultrasound Obstet Gynecol"},{"key":"708_CR34","first-page":"98","volume":"43","author":"RH Zheng","year":"2008","unstructured":"Zheng RH, Ding CF (2008) Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study. Zhonghua Fu Chan Ke Za Zhi 43:98\u2013101","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"708_CR35","first-page":"2036","volume":"90","author":"ZY Qu","year":"2010","unstructured":"Qu ZY, Shi YH, Zhao DN, Jiang JJ, Ma ZX, Chen ZJ (2010) Effect of obesity on nonalcoholic fatty liver disease in Chinese women with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 90:2036\u20132039","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"708_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.14310\/horm.2002.1493","volume":"13","author":"SA Polyzos","year":"2014","unstructured":"Polyzos SA, Goulis DG, Kountouras J, Mintziori G, Chatzis P, Papadakis E, Katsikis I, Panidis D (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones (Athens) 13:519\u2013531. doi: 10.14310\/horm.2002.1493","journal-title":"Hormones (Athens)"},{"key":"708_CR37","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/humrep\/dew076","volume":"31","author":"D Macut","year":"2016","unstructured":"Macut D, Tziomalos K, Bo\u017ei\u0107-Anti\u0107 I, Bjeki\u0107-Macut J, Katsikis I, Papadakis E, Andri\u0107 Z, Panidis D (2016) Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 31:1347\u20131353. doi: 10.1093\/humrep\/dew076","journal-title":"Hum Reprod"},{"key":"708_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0974-1208.112370","volume":"6","author":"R Karoli","year":"2013","unstructured":"Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G (2013) Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci 6:9\u201314. doi: 10.4103\/0974-1208.112370","journal-title":"J Hum Reprod Sci"},{"key":"708_CR39","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5603\/EP.2014.0058","volume":"65","author":"A Bohdanowicz-Pawlak","year":"2014","unstructured":"Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, Kuliczkowska-P\u0142aksej J, \u0141aczma\u0144ski \u0141, Zaleska-Dorobisz U, Milewicz A (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome\u2014Clinical and metabolic aspects and lipoprotein lipase gene polymorphism. Endokrynologia Polska 65:416\u2013421. doi: 10.5603\/EP.2014.0058","journal-title":"Endokrynologia Polska"},{"key":"708_CR40","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/jgh.13241","volume":"31","author":"OT Ayonrinde","year":"2016","unstructured":"Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, Sloboda DM, Olynyk JK, Hart R (2016) Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. J Gastroenterol Hepatol 31:980\u2013987. doi: 10.1111\/jgh.13241","journal-title":"J Gastroenterol Hepatol"},{"key":"708_CR41","first-page":"867","volume":"1","author":"RH Srinivas-Prasad","year":"2014","unstructured":"Srinivas-Prasad RH, Balakrishna BV, Kudva N, Sandhya H, Ramakrishna P (2014) Incidence of non-alcoholic hepatic fatty infiltration in women with polycystic ovary syndrome. J Evid Med Healthc 1:867\u2013875","journal-title":"J Evid Med Healthc"},{"key":"708_CR42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1721727X1301100117","volume":"11","author":"G Tarantino","year":"2013","unstructured":"Tarantino G, Di Somma C, Pizza G, Brancato V, Nedi V, Valentino R, Orio F, Pivonello C, Colao A, Savastano S (2013) Polycystic ovary syndrome and hepatic steatosis: could low-grade chronic inflammation be mediated by the spleen? Eur J Inflamm 11:179\u2013191","journal-title":"Eur J Inflamm"},{"key":"708_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2017.116","author":"C Jie","year":"2017","unstructured":"Jie C, Chunhua W, Yi Z, Yuying W, Wendi X, Tzuchun L, Shengxian L, Lihua W, Jun Z, Yun S, Wei L, Tao T (2017) High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. Int J Obes (Lond). doi: 10.1038\/ijo.2017.116","journal-title":"Int J Obes (Lond)"},{"key":"708_CR44","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/apt.14058","volume":"45","author":"JJ Kim","year":"2017","unstructured":"Kim JJ, Kim D, Yim JY, Kang JH, Han KH, Kim SM, Hwang KR, Ku SY, Suh CS, Kim SH, Choi YM (2017) Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther 45:1403\u20131412. doi: 10.1111\/apt.14058","journal-title":"Aliment Pharmacol Ther"},{"key":"708_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/09513590903184084","volume":"26","author":"RP Kauffman","year":"2010","unstructured":"Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD (2010) Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 26:39\u201346. doi: 10.3109\/09513590903184084","journal-title":"Gynecol Endocrinol"},{"key":"708_CR46","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1210\/jc.2012-1382","volume":"97","author":"H Jones","year":"2012","unstructured":"Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ (2012) Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 97:3709\u20133716. doi: 10.1210\/jc.2012-1382","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14310\/horm.2002.1236","volume":"8","author":"F Economou","year":"2009","unstructured":"Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E (2009) In overweight\/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 8:199\u2013206","journal-title":"Hormones (Athens)"},{"key":"708_CR48","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1210\/jc.2012-3698","volume":"98","author":"S Borruel","year":"2013","unstructured":"Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2013) Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98:1254\u20131263. doi: 10.1210\/jc.2012-3698","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR49","doi-asserted-by":"publisher","first-page":"e23235","DOI":"10.5812\/hepatmon.23235","volume":"14","author":"M Ramezani-Binabaj","year":"2014","unstructured":"Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM (2014) Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon 14:e23235. doi: 10.5812\/hepatmon.23235","journal-title":"Hepat Mon"},{"key":"708_CR50","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2004-1045","volume":"90","author":"T Apridonidze","year":"2005","unstructured":"Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929\u20131935. doi: 10.1210\/jc.2004-1045","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2174\/1567201812666150120163025","volume":"13","author":"G Daskalopoulos","year":"2015","unstructured":"Daskalopoulos G, Karkanaki A, Piouka A, Prapas N, Panidis D, Gkeleris P, Athyros VG (2015) Excess metabolic and cardiovascular risk is not manifested in all phenotypes of polycystic ovary syndrome: implications for diagnosis and treatment. Curr Vasc Pharmacol 13:788\u2013800","journal-title":"Curr Vasc Pharmacol"},{"key":"708_CR52","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/cen.12258","volume":"80","author":"AJ Dawson","year":"2014","unstructured":"Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL (2014) A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 80:843\u2013849. doi: 10.1111\/cen.12258","journal-title":"Clin Endocrinol (Oxf)"},{"key":"708_CR53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1210\/jc.2009-1834","volume":"95","author":"S Tan","year":"2010","unstructured":"Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A (2010) Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95:343\u2013348. doi: 10.1210\/jc.2009-1834","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR54","doi-asserted-by":"publisher","first-page":"14172","DOI":"10.3748\/wjg.v20.i39.14172","volume":"20","author":"CE Kelley","year":"2014","unstructured":"Kelley CE, Brown AJ, Diehl AM, Setji TL (2014) Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 20:14172\u201314184. doi: 10.3748\/wjg.v20.i39.14172","journal-title":"World J Gastroenterol"},{"key":"708_CR55","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367\u2013378. doi: 10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"708_CR56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/cen.12369","volume":"81","author":"H Kahal","year":"2014","unstructured":"Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL (2014) Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 81:523\u2013528. doi: 10.1111\/cen.12369","journal-title":"Clin Endocrinol (Oxf)"},{"key":"708_CR57","doi-asserted-by":"publisher","first-page":"E1645","DOI":"10.1210\/jc.2011-1093","volume":"96","author":"M Aubuchon","year":"2011","unstructured":"Aubuchon M, Kunselman AR, Schlaff WD, Diamond MP, Coutifaris C, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Legro RS (2011) Metformin and\/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96:E1645\u20131649. doi: 10.1210\/jc.2011-1093","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR58","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1055\/s-0032-1328878","volume":"30","author":"RS Legro","year":"2012","unstructured":"Legro RS (2012) Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 30:496\u2013506. doi: 10.1055\/s-0032-1328878","journal-title":"Semin Reprod Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-017-0708-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T19:59:41Z","timestamp":1569441581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-017-0708-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s40618-017-0708-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,13]]}}}